| Interaction |
Description |
|
acebutolol -
tolbutamide
|
Decreased in symptoms of hypoglycemia and increase in time required for the body to compensate for hypoglycemia
(source: Drug Bank
)
|
|
acebutolol -
tolbutamide
|
Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
(source: Drug Bank
)
|
|
aspirin -
tolbutamide
|
The salicylate increases the effect of sulfonylurea
(source: Drug Bank
)
|
|
aspirin -
tolbutamide
|
Acetylsalicylic acid increases the effect of the sulfonylurea, tolbutamide.
(source: Drug Bank
)
|
|
atenolol -
tolbutamide
|
The beta-blocker decreases the symptoms of hypoglycemia
(source: Drug Bank
)
|
|
atenolol -
tolbutamide
|
The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
(source: Drug Bank
)
|
|
bisoprolol -
tolbutamide
|
The beta-blocker decreases the symptoms of hypoglycemia
(source: Drug Bank
)
|
|
bisoprolol -
tolbutamide
|
The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
(source: Drug Bank
)
|
|
carvedilol -
tolbutamide
|
The beta-blocker decreases the symptoms of hypoglycemia
(source: Drug Bank
)
|
|
carvedilol -
tolbutamide
|
The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
(source: Drug Bank
)
|
|
chloramphenicol -
tolbutamide
|
The agent increases the effect of sulfonylurea
(source: Drug Bank
)
|
|
chloramphenicol -
tolbutamide
|
The agent increases the effect of sulfonylurea
(source: Drug Bank
)
|
|
clofibrate -
tolbutamide
|
The agent increases the effect of sulfonylurea
(source: Drug Bank
)
|
|
clofibrate -
tolbutamide
|
The agent increases the effect of sulfonylurea
(source: Drug Bank
)
|
|
digoxin -
tolbutamide
|
Tolbutamide increases the effect of digoxin
(source: Drug Bank
)
|
|
digoxin -
tolbutamide
|
Tolbutamide increases the effect of digoxin
(source: Drug Bank
)
|
|
esmolol -
tolbutamide
|
The beta-blocker decreases the symptoms of hypoglycemia
(source: Drug Bank
)
|
|
esmolol -
tolbutamide
|
The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
(source: Drug Bank
)
|
|
isocarboxazid -
tolbutamide
|
The MAO inhibitor increases the effect of hypoglycemic agent
(source: Drug Bank
)
|
|
ketoconazole -
tolbutamide
|
Ketoconazole increases the effect and toxicity of tolbutamide
(source: Drug Bank
)
|
|
ketoconazole -
tolbutamide
|
Ketoconazole increases the effect and toxicity of tolbutamide
(source: Drug Bank
)
|
|
labetalol -
tolbutamide
|
The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
(source: Drug Bank
)
|
|
metoprolol -
tolbutamide
|
The beta-blocker decreases the symptoms of hypoglycemia
(source: Drug Bank
)
|
|
metoprolol -
tolbutamide
|
The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
(source: Drug Bank
)
|
|
nadolol -
tolbutamide
|
The beta-blocker decreases the symptoms of hypoglycemia
(source: Drug Bank
)
|
|
nadolol -
tolbutamide
|
The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
(source: Drug Bank
)
|
|
oxprenolol -
tolbutamide
|
The beta-blocker decreases the symptoms of hypoglycemia
(source: Drug Bank
)
|
|
oxprenolol -
tolbutamide
|
The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
(source: Drug Bank
)
|
|
phenelzine -
tolbutamide
|
The MAO inhibitor increases the effect of the hypoglycemic agent
(source: Drug Bank
)
|
|
phenylbutazone -
tolbutamide
|
Phenylbutazone increases the effect of the hypoglycemic agent
(source: Drug Bank
)
|
|
phenylbutazone -
tolbutamide
|
Phenylbutazone increases the effect of the hypoglycemic agent
(source: Drug Bank
)
|
|
pindolol -
tolbutamide
|
The beta-blocker decreases the symptoms of hypoglycemia
(source: Drug Bank
)
|
|
pindolol -
tolbutamide
|
The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
(source: Drug Bank
)
|
|
propranolol -
tolbutamide
|
The beta-blocker decreases the symptoms of hypoglycemia
(source: Drug Bank
)
|
|
propranolol -
tolbutamide
|
The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
(source: Drug Bank
)
|
|
repaglinide -
tolbutamide
|
Similar mode of action - questionable association
(source: Drug Bank
)
|
|
rifampin -
tolbutamide
|
Rifampin decreases the effect of sulfonylurea
(source: Drug Bank
)
|
|
rifampin -
tolbutamide
|
Rifampin decreases the effect of sulfonylurea
(source: Drug Bank
)
|
|
tamoxifen -
tolbutamide
|
Tolbutamide may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tamoxifen -
tolbutamide
|
Tolbutamide may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
timolol -
tolbutamide
|
The beta-blocker decreases the symptoms of hypoglycemia
(source: Drug Bank
)
|
|
timolol -
tolbutamide
|
The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
(source: Drug Bank
)
|
|
tolbutamide -
acenocoumarol
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Acenocoumarol. Consider alternate therapy or monitor for changes in Acenocoumarol therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
acenocoumarol
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Acenocoumarol. Consider alternate therapy or monitor for changes in Acenocoumarol therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
bosentan
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Bosentan. Consider alternate therapy or monitor for changes in Bosentan therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
bosentan
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Bosentan. Consider alternate therapy or monitor for changes in Bosentan therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
capecitabine
|
Capecitabine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Capecitabine is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
capecitabine
|
Capecitabine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Capecitabine is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
celecoxib
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Celecoxib. Consider alternate therapy or monitor for changes in Celecobix therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
celecoxib
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Celecoxib. Consider alternate therapy or monitor for changes in Celecobix therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
dapsone
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Dapsone. Consider alternate therapy or monitor for changes in Dapsone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
dapsone
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Dapsone. Consider alternate therapy or monitor for changes in Dapsone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
delavirdine
|
Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Delavirdine is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
delavirdine
|
Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Delavirdine is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
floxuridine
|
Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Floxuridine is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
floxuridine
|
Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Floxuridine is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
fluconazole
|
Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Fluconazole therapeutic and adverse effects if Delavirdine is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
fluconazole
|
Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Fluconazole therapeutic and adverse effects if Delavirdine is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
fluorouracil
|
Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Fluorouracil is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
fluorouracil
|
Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Fluorouracil is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
fluoxetine
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Fluoxetine. Consider alternate therapy or monitor for changes in Fluoxetine therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
fluoxetine
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Fluoxetine. Consider alternate therapy or monitor for changes in Fluoxetine therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
flurbiprofen
|
Flurbiprofen, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Flurbiprofen is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
flurbiprofen
|
Flurbiprofen, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Flurbiprofen is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
fosphenytoin
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Fosphenytoin. Consider alternate therapy or monitor for changes in Fosphenytoin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
fosphenytoin
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Fosphenytoin. Consider alternate therapy or monitor for changes in Fosphenytoin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
gemfibrozil
|
Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Gemfibrozil is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
gemfibrozil
|
Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Gemfibrozil is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
glimepiride
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Glimepiride. Consider alternate therapy or monitor for changes in Glimepiride therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
glimepiride
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Glimepiride. Consider alternate therapy or monitor for changes in Glimepiride therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
glipizide
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Glipizide. Consider alternate therapy or monitor for changes in Glipizide therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
glipizide
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Glipizide. Consider alternate therapy or monitor for changes in Glipizide therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
ibuprofen
|
Ibuprofen, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ibuprofen is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
ibuprofen
|
Ibuprofen, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ibuprofen is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
indomethacin
|
Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Indomethacin is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
indomethacin
|
Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Indomethacin is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
ketamine
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Ketamine. Consider alternate therapy or monitor for changes in Ketamine therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
ketamine
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Ketamine. Consider alternate therapy or monitor for changes in Ketamine therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
ketoconazole
|
Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
ketoconazole
|
Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
losartan
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Losartan. Consider alternate therapy or monitor for changes in Losartan therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
losartan
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Losartan. Consider alternate therapy or monitor for changes in Losartan therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
lumiracoxib
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Lumiracoxib. Consider alternate therapy or monitor for changes in Lumiracoxib therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
lumiracoxib
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Lumiracoxib. Consider alternate therapy or monitor for changes in Lumiracoxib therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
mestranol
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Mestranol. Consider alternate therapy or monitor for changes in Mestranol therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
mestranol
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Mestranol. Consider alternate therapy or monitor for changes in Mestranol therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
miconazole
|
Miconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Miconazole is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
miconazole
|
Miconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Miconazole is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
montelukast
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Montelukast. Consider alternate therapy or monitor for changes in Montelukast therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
montelukast
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Montelukast. Consider alternate therapy or monitor for changes in Montelukast therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
nateglinide
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Nateglinide. Consider alternate therapy or monitor for changes in Nateglinide therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
nateglinide
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Nateglinide. Consider alternate therapy or monitor for changes in Nateglinide therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
nicardipine
|
Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Nicardipine is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
nicardipine
|
Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Nicardipine is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
paclitaxel
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Paclitaxel. Consider alternate therapy or monitor for changes in Paclitaxel therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
paclitaxel
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Paclitaxel. Consider alternate therapy or monitor for changes in Paclitaxel therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
phenytoin
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Phenytoin. Consider alternate therapy or monitor for changes in Phenytoin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
phenytoin
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Phenytoin. Consider alternate therapy or monitor for changes in Phenytoin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
piroxicam
|
Piroxicam, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Piroxicam is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
piroxicam
|
Piroxicam, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Piroxicam is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
somatropin recombinant
|
Somatropin may antagonize the hypoglycemic effect of Tolbutamide. Dose adjustments of Tolbutamide may be required.
(source: Drug Bank
)
|
|
tolbutamide -
somatropin recombinant
|
Somatropin may antagonize the hypoglycemic effect of Tolbutamide. Dose adjustments of Tolbutamide may be required.
(source: Drug Bank
)
|
|
tolbutamide -
sulfadiazine
|
Tolbutamide and Sulfadiazine are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed.
(source: Drug Bank
)
|
|
tolbutamide -
sulfadiazine
|
Tolbutamide and Sulfadiazine are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed.
(source: Drug Bank
)
|
|
tolbutamide -
sulfamethoxazole
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Sulfamethoxazole. Consider alternate therapy or monitor for changes in Sulfamethoxazole therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
sulfamethoxazole
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Sulfamethoxazole. Consider alternate therapy or monitor for changes in Sulfamethoxazole therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
sulfinpyrazone
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Sulfinpyrazone. Consider alternate therapy or monitor for changes in Sulfinpyrazone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
sulfinpyrazone
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Sulfinpyrazone. Consider alternate therapy or monitor for changes in Sulfinpyrazone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
sulfisoxazole
|
Tolbutamide and Sulfisoxazole are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed.
(source: Drug Bank
)
|
|
tolbutamide -
sulfisoxazole
|
Tolbutamide and Sulfisoxazole are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed.
(source: Drug Bank
)
|
|
tolbutamide -
tamoxifen
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tamoxifen. Consider alternate therapy or monitor for changes in Tamoxifen therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
tamoxifen
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tamoxifen. Consider alternate therapy or monitor for changes in Tamoxifen therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
torasemide
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Torasemide. Consider alternate therapy or monitor for changes in Torasemide therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
torasemide
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Torasemide. Consider alternate therapy or monitor for changes in Torasemide therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
trimethoprim
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Trimethoprim. Consider alternate therapy or monitor for changes in Trimethoprim therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
trimethoprim
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Trimethoprim. Consider alternate therapy or monitor for changes in Trimethoprim therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
voriconazole
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Voriconazole. Consider alternate therapy or monitor for changes in Voriconazole therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
voriconazole
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Voriconazole. Consider alternate therapy or monitor for changes in Voriconazole therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
warfarin
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Warfarin. Consider alternate therapy or monitor for changes in Warfarin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
warfarin
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Warfarin. Consider alternate therapy or monitor for changes in Warfarin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
zafirlukast
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Zafirlukast. Consider alternate therapy or monitor for changes in Zafirlukast therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
zafirlukast
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Zafirlukast. Consider alternate therapy or monitor for changes in Zafirlukast therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
zopiclone
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Zopiclone. Consider alternate therapy or monitor for changes in Zopiclone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
tolbutamide -
zopiclone
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Zopiclone. Consider alternate therapy or monitor for changes in Zopiclone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
torasemide -
tolbutamide
|
Tolbutamide, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
trimethoprim -
tolbutamide
|
The strong CYP2C9 inhibitor, Tolbutamide, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
voriconazole -
tolbutamide
|
Tolbutamine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
warfarin -
tolbutamide
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
zafirlukast -
tolbutamide
|
Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if tolbutamide is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
